Company intelligence / Profile preview

Ore Pharmaceuticals

Gaithersburg, Maryland, United Statesorepharma.com ↗

Ownership: Private
Development stage: Other

Overview

Ore Pharmaceuticals focused on identifying new indications for existing clinical-stage compounds using a proprietary integrative pharmacology platform. Lead programs included GL1001 for gastrointestinal disorders, romazarit for metabolic diseases, tiapamil hydrochloride for CNS disorders, and SCH‑58500 targeting p53 in oncology. Some programs reached Phase II or were pending further development/outlicensing. The company ceased active operations after 2011.

Therapeutic areas: GastroenterologyOncologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

ORE1001

2 more assets in the full pipeline.

Partnerships

Roche (in-license/development rights to romazarit and other compounds)Steel Partners Ltd. (major investor with board representation post-investment)

Beyond the preview

Go deeper on Ore Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ore Pharmaceuticals.